Advances in Clinical Chemistry (eBook)
240 Seiten
Elsevier Science (Verlag)
978-0-12-800303-9 (ISBN)
Volume 65 in the internationally acclaimed Advances in Clinical Chemistry contains chapters authored by world renowned clinical laboratory scientists, physicians and research scientists. The serial provides the latest and most up-to-date technologies related to the field of Clinical Chemistry and is the benchmark for novel analytical approaches in the clinical laboratory. - Expertise of international contributors- Latest cutting-edge technologies- Comprehensive in scope
Diagnosis of Infection in Critical Care
Belén Prieto*; Francisco V. Álvarez Menéndez*,†,1 * Clinical Biochemistry, Laboratory of Medicine, Hospital Universitario Central de Asturias, Oviedo, Spain
† Biochemistry and Molecular Biology Department, University of Oviedo, Oviedo, Spain
1 Corresponding author: email address: falvarezmen@gmail.com
Abstract
Sepsis is the primary cause of death in the intensive care unit. The prevention of sepsis complications requires an early and accurate diagnosis as well as the appropriate monitoring. A deep knowledge of the immunologic basis of sepsis is essential to better understand the scope of incorporating a new marker into clinical practice.
Besides revising this theoretical aspect, the current available tools for bacterial identification have been briefly reviewed as well as a variety of new markers showing either well-recognized or potential usefulness for diagnosis and prognosis of infections in critically ill patients. Particular conditions such as community-acquired pneumonia, pediatric sepsis, or liver transplantation, among others, have been separately treated, since the optimal approaches and markers might be different in these special cases.
Keywords
Biomarkers
Infection
Sepsis
Systemic inflammatory response syndrome
Abbreviations
AdVs adenoviruses
AKI acute kidney injury
AUC area under the curve
BC blood culture
CAP community-acquired pneumonia
cfDNA cell-free DNA
CI confidence interval
CNS central nervous system
CRP C-reactive protein
CT-proET-1 carboxyterminal fragment of proendotelin-1
DAMPs danger-associated molecular patterns
GCS Glasgow Coma Scale
HMGB-1 high-mobility group box-1
ICU intensive care unit
IL interleukin
iNOS inducible nitric oxide synthase
MALDI matrix-assisted laser desorption ionization
MR-proADM midregional proadrenomedullin
MR-proANP medium region of pro A-type natriuretic peptide
MS mass spectrometry
NF-κB nuclear factor κB
NO nitric oxide
NSE neuron-specific enolase
OLT orthotopic liver transplantation
PAI-1 plasminogen activator inhibitor type 1
PCT procalcitonin
PRR pattern-recognition receptors
PSI pneumonia severity index
PSP/reg pancreatic stone peptide/regenerating peptide
SIRS systemic inflammatory response syndrome
ST signal transduction
TF transcription factor
TFPI tissue factor pathway inhibitor
TLRs toll-like receptors
TNF tumoral necrosis factor
TOF time of flight
1 Background
Sepsis is the primary cause of death in the intensive care unit (ICU). Early antibiotic therapy plays a crucial role on the prognosis of these patients. The prevention of sepsis complications requires an early and accurate diagnosis as well as the appropriate monitoring. At present, most microbiological laboratories are limited by poor sensitivity and the time-consuming nature of culture-based methods. The clinical symptoms of the septic patient are often masked by systemic inflammatory response processes, infectious or not, and treatments. The diagnostic difficulty of sepsis is even more relevant in both pediatric and adult ICUs, where patients are at increased risk because of not only their critical state and immunological vulnerability but also the use of invasive techniques (e.g., mechanical ventilation) and nonspecific symptoms. Moreover, the preventive administration of antibiotics in critical care patients increases resistance and the risk of hospital-acquired infections. On the other hand, time factor also plays an important role in the prognosis of sepsis, since a delay in the identification and appropriate management of critical patients during the first 6 h of admission to the ICU is associated with higher mortality [1].
The concept of systemic inflammatory response syndrome (SIRS) was established for the first time at the Sepsis Consensus Conference held in 1992 by the Society of Critical Care Medicine and the American College of Chest Physicians [2]. Since then, SIRS has been defined according to well-established criteria (Table 2.1), without the need for the demonstration of the presence of bacterial infection by microbiological culture, whereas sepsis is considered as a SIRS in response to documented infection that can lead to severe consequences, including multiple organ failure.
Table 2.1
SIRS definition requires showing two or more of the following conditions
Temperature | < 36 °C or > 38 °C |
Heart rate | > 90 beats/min, in absence of pain or anemia |
Respiratory rate | > 20 breaths/min or PaCO2 < 32 mmHg |
WBC count | > 12,000 cells/μL or > 10% immature (band) forms |
Other stages of sepsis were also defined, such as severe sepsis, associated with organ dysfunction, hypoperfusion or hypotension, and septic shock, the most severe stage of sepsis, cursing with arterial hypotension despite adequate fluid resuscitation.
The differentiation between infectious SIRS and other etiologies, as well as the stratification of the disease progression in these three stages, is very important, since their management and evolution are quite different [3].
However, the clinical application of these definitions quickly demonstrated that they lacked sufficient diagnostic efficiency. The presence of clinical signs of inflammation is shown in both infectious and noninfectious processes, microbiological culture being the reference differential diagnostic tool. The development of new biochemical markers of inflammation, such as C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6), improved the differentiation of both clinical situations, thus allowing the redefinition of SIRS and sepsis in the International Sepsis Definition Conference in 2001 [4]. By this time, a new staging system was established, named PIRO system (from Predisposition, Infection, Response, and Organ Dysfunction) aimed at stratifying patients based on not only the clinical features but also the biochemical markers of inflammation (Fig. 2.1; Ref. [5]).
From a more clinical perspective, it has been recently proposed to include evidence of organ dysfunction in the criteria for sepsis [6]. Of note, this slightly differs from the definition used in the recently published guidelines of the Surviving Sepsis Campaign in which sepsis is defined clinically as the presence (probable or documented) of infection together with systemic manifestations of infection and severe sepsis is defined as sepsis with sepsis-induced organ dysfunction or tissue hypoperfusion [7].
Despite the great advance in our knowledge on the pathogenesis of sepsis, severe sepsis, defined as sepsis with organ failure, remains associated with an unacceptable high mortality [8].
2 Immunologic Basis of Sepsis
The inflammatory process starts as a response mediated by cellular and humoral factors that seek to limit, eliminate, and repair the lesion caused by the infectious agent. This inflammatory response is sometimes exaggerated and not limited only to the lesion point, thus spreading to the entire organism and leading to a SIRS.
Activating agents, infectious or not, will be recognized by immune system cells by surface receptors (Fig. 2.2; Ref. [9]). SIRS begins with a rapid release of proinflammatory cytokines (IL-1α, IL-1β, IL-2, IL-6, IL-8, IL-15, IL-18, and α-tumoral necrosis factor or TNF-α), as well as immunological cytokines, γ-interferon, and TNF-β. Liberation of proinflammatory cytokines is very fast, and they are rapidly cleared from systemic circulation. TNF-α plays a central role in the pathogenesis of SIRS: it is released into peripheral blood...
Erscheint lt. Verlag | 20.5.2014 |
---|---|
Mitarbeit |
Herausgeber (Serie): Gregory S. Makowski |
Sprache | englisch |
Themenwelt | Medizinische Fachgebiete ► Innere Medizin ► Endokrinologie |
Medizin / Pharmazie ► Medizinische Fachgebiete ► Laboratoriumsmedizin | |
Studium ► 1. Studienabschnitt (Vorklinik) ► Biochemie / Molekularbiologie | |
Studium ► 2. Studienabschnitt (Klinik) ► Anamnese / Körperliche Untersuchung | |
Naturwissenschaften ► Biologie ► Biochemie | |
Naturwissenschaften ► Physik / Astronomie ► Angewandte Physik | |
ISBN-10 | 0-12-800303-0 / 0128003030 |
ISBN-13 | 978-0-12-800303-9 / 9780128003039 |
Haben Sie eine Frage zum Produkt? |
Größe: 7,6 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belletristik und Sachbüchern. Der Fließtext wird dynamisch an die Display- und Schriftgröße angepasst. Auch für mobile Lesegeräte ist EPUB daher gut geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Zusätzliches Feature: Online Lesen
Dieses eBook können Sie zusätzlich zum Download auch online im Webbrowser lesen.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich